PDE6): Similarities and Differences to PDE5
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Regulation of Calcium/Calmodulin-Dependent Protein Kinase II Activation by Intramolecular and Intermolecular Interactions
8394 • The Journal of Neuroscience, September 29, 2004 • 24(39):8394–8398 Mini-Review Regulation of Calcium/Calmodulin-Dependent Protein Kinase II Activation by Intramolecular and Intermolecular Interactions Leslie C. Griffith Department of Biology and Volen Center for Complex Systems, Brandeis University, Waltham, Massachusetts 02454-9110 Key words: calcium; calmodulin; learning; localization; NMDA; phosphatase; protein kinase As its name implies, calcium/calmodulin-dependent protein ki- The overlap of these subdomains is no accident. Binding of nase II (CaMKII) is calcium dependent. In its basal state, the Ca 2ϩ/CaM is the primary signal for release of autoinhibition. activity of CaMKII is extremely low. Regulation of intracellular Current models of activation posit that the binding of Ca 2ϩ/CaM calcium levels allows the neuron to link activity with phosphor- serves to disrupt the interactions of specific residues within the ylation by CaMKII. This review will briefly summarize our cur- autoinhibitory domain with the catalytic domain (Smith et al., rent understanding of the intramolecular mechanisms of activity 1992). Because there is no crystal structure for the catalytic and regulation and their modulation by Ca 2ϩ/CaM and will then regulatory parts of CaMKII, the interaction face of these two focus on the growing number of other modes of intermolecular domains has been inferred using the effects of charge-reversal regulation of CaMKII activity by substrate and scaffolding mutagenesis on activity and molecular modeling (Yang and molecules. Schulman, 1999). This study confirmed the role of Arg 297 at the P-3 position of the pseudosubstrate ligand (Mukherji and Soder- Regulation of CaMKII by its autoinhibitory domain ling, 1995) and identified residues in the catalytic domain that All members of the CaMKII family (␣, , ␥, and ␦ isozymes) share may have direct interactions with the regulatory region. -
Reprogramming Metabolism by Targeting Sirtuin 6 Attenuates Retinal Degeneration
The Journal of Clinical Investigation RESEARCH ARTICLE Reprogramming metabolism by targeting sirtuin 6 attenuates retinal degeneration Lijuan Zhang,1,2,3 Jianhai Du,4 Sally Justus,1,2 Chun-Wei Hsu,1,2 Luis Bonet-Ponce,5 Wen-Hsuan Wu,1,2 Yi-Ting Tsai,1,2 Wei-Pu Wu,1,2 Yading Jia,2 Jimmy K. Duong,6 Vinit B. Mahajan,7 Chyuan-Sheng Lin,8 Shuang Wang,6 James B. Hurley,4 and Stephen H. Tsang1,2,9 1The Jonas Children’s Vision Care and Bernard & Shirlee Brown Glaucoma Laboratory, Department of Ophthalmology, Columbia University, New York, New York, USA. 2Edward S. Harkness Eye Institute, New York-Presbyterian Hospital, New York, New York, USA. 3Shanxi Eye Hospital, affiliated with Shanxi Medical University, Xinghualing, Taiyuan, China. 4Department of Biochemistry and Ophthalmology, University of Washington, Seattle, Washington, USA. 5Section on Retinal Ganglion Cell Biology, Laboratory of Retinal Cell and Molecular Biology, NIH, Bethesda, Maryland, USA. 6Department of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, New York, USA. 7Omics Lab, University of Iowa, Iowa City, Iowa, USA. 8Department of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons of Columbia University, New York, New York, USA. 9Departments of Pathology and Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, New York, New York, USA. Retinitis pigmentosa (RP) encompasses a diverse group of Mendelian disorders leading to progressive degeneration of rods and then cones. For reasons that remain unclear, diseased RP photoreceptors begin to deteriorate, eventually leading to cell death and, consequently, loss of vision. -
RPE65 Mutant Dog/ Leber Congenital Amaurosis
Rpe65 mutant dogs Pde6A mutant dogs Cngb1 mutant dogs rAAV RPE65 Mutant Dog/ Leber Congenital Amaurosis Null mutation in Rpe65 retinal function (ERG & dim light vision) Failure of 11-cis retinal supply to photoreceptors (visual cycle) Retina only slow degeneration (S-cones and area centralis degeneration – variable) RPE lipid inclusions 8 Mo 3.5 yr The Visual (Retinoid) Cycle retinal pigment All-trans-retinol epithelium (Vitamin A) RPE65 11-cis-retinal Visual pigments All-trans-retinal rod and cone outer segments All-trans-retinol Gene supplementation therapy for RPE65 Leber Congenital Amaurosis Initial trials in dogs – very successful Outcome in humans Some improvement in visual function Appears to not preserve photoreceptors in longer term Questions Is there preservation of photoreceptors? Why is outcome in humans not so successful? Does RPE65 Gene Therapy Preserve Photoreceptors? Rpe65-/- dogs: Early loss of S-cones Slow LM cone loss Very slow rod loss Exception – region of high density of photoreceptors – rapid loss Gene therapy preservation of photoreceptors Limitations to Human Functional Rescue and Photoreceptor Preservation Hypothesis The dose of gene therapy delivered is a limiting factor for the efficacy of treatment Specific aim To compare the clinical efficacy and the levels of expression of RPE65 protein and the end product of RPE65 function (11-cis retinal) of various doses of RPE65 gene therapy in Rpe65 -/- dogs Methods Tested total dose of 8x108 to 1x1011 vg/eye ERG Scotopic b wave Vision testing % correct choice RPE65 protein expression Dose of gene therapy +/+ 8x108 4x109 2x1010 1x1011 RPE65 GAPDH RPE65 protein expression RPE65/DAPI/ autofluorescence Chromophore levels 11-cis retinal levels undetectable In Rpe65 -/- All-trans retinal Chromophore vs clinical outcomes Scotopic b wave r2 = 0.91 p < 0.0001 Vision testing % correct choice r2 = 0.58 p = 0.02 RPE65 gene expression Human vs. -
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
A Multistep Bioinformatic Approach Detects Putative Regulatory
BMC Bioinformatics BioMed Central Research article Open Access A multistep bioinformatic approach detects putative regulatory elements in gene promoters Stefania Bortoluzzi1, Alessandro Coppe1, Andrea Bisognin1, Cinzia Pizzi2 and Gian Antonio Danieli*1 Address: 1Department of Biology, University of Padova – Via Bassi 58/B, 35131, Padova, Italy and 2Department of Information Engineering, University of Padova – Via Gradenigo 6/B, 35131, Padova, Italy Email: Stefania Bortoluzzi - [email protected]; Alessandro Coppe - [email protected]; Andrea Bisognin - [email protected]; Cinzia Pizzi - [email protected]; Gian Antonio Danieli* - [email protected] * Corresponding author Published: 18 May 2005 Received: 12 November 2004 Accepted: 18 May 2005 BMC Bioinformatics 2005, 6:121 doi:10.1186/1471-2105-6-121 This article is available from: http://www.biomedcentral.com/1471-2105/6/121 © 2005 Bortoluzzi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Searching for approximate patterns in large promoter sequences frequently produces an exceedingly high numbers of results. Our aim was to exploit biological knowledge for definition of a sheltered search space and of appropriate search parameters, in order to develop a method for identification of a tractable number of sequence motifs. Results: Novel software (COOP) was developed for extraction of sequence motifs, based on clustering of exact or approximate patterns according to the frequency of their overlapping occurrences. -
Impedes Transport of GRK1 and PDE6 Catalytic Subunits to Photoreceptor Outer Segments
Deletion of PrBP/␦ impedes transport of GRK1 and PDE6 catalytic subunits to photoreceptor outer segments H. Zhang*, S. Li*, T. Doan†, F. Rieke†‡, P. B. Detwiler†, J. M. Frederick*, and W. Baehr*§¶ʈ *John A. Moran Eye Center, University of Utah Health Science Center, Salt Lake City, UT 84132; †Department of Physiology and Biophysics and ‡Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195; and Departments of §Neurobiology and Anatomy and ¶Biology, University of Utah, Salt Lake City, UT 84112 Edited by Jeremy Nathans, Johns Hopkins University School of Medicine, Baltimore, MD, and approved April 11, 2007 (received for review February 23, 2007) The mouse Pde6d gene encodes a ubiquitous prenyl binding chains (5, 7). Posttranslational sorting and targeting of proteins protein, termed PrBP/␦, of largely unknown physiological function. occurs in all cells and is of particular importance in photore- PrBP/␦ was originally identified as a putative rod cGMP phospho- ceptors, which renew their entire outer segments roughly every diesterase (PDE6) subunit in the retina, where it is relatively 10 days (8). Because of compartmentalization of inner and outer abundant. To investigate the consequences of Pde6d deletion in segments and very active metabolism, photoreceptors are re- .retina, we generated a Pde6d؊/؊ mouse by targeted recombina- garded as model cells to study protein trafficking tion. Although manifesting reduced body weight, the Pde6d؊/؊ PrBP/␦, originally thought to be a subunit of PDE6 and termed mouse was viable and fertile and its retina developed normally. PDE␦ (9), was shown recently to be a prenyl binding protein (10, Immunocytochemistry showed that farnesylated rhodopsin kinase 11) and subsequently named PrBP/␦ to reflect this fact (12). -
Regulation of Calmodulin-Stimulated Cyclic Nucleotide Phosphodiesterase (PDE1): Review
95-105 5/6/06 13:44 Page 95 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 18: 95-105, 2006 95 Regulation of calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1): Review RAJENDRA K. SHARMA, SHANKAR B. DAS, ASHAKUMARY LAKSHMIKUTTYAMMA, PONNIAH SELVAKUMAR and ANURAAG SHRIVASTAV Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Cancer Research Division, Saskatchewan Cancer Agency, 20 Campus Drive, Saskatoon SK S7N 4H4, Canada Received January 16, 2006; Accepted March 13, 2006 Abstract. The response of living cells to change in cell 6. Differential inhibition of PDE1 isozymes and its environment depends on the action of second messenger therapeutic applications molecules. The two second messenger molecules cAMP and 7. Role of proteolysis in regulating PDE1A2 Ca2+ regulate a large number of eukaryotic cellular events. 8. Role of PDE1A1 in ischemic-reperfused heart Calmodulin-stimulated cyclic nucleotide phosphodiesterase 9. Conclusion (PDE1) is one of the key enzymes involved in the complex interaction between cAMP and Ca2+ second messenger systems. Some PDE1 isozymes have similar kinetic and 1. Introduction immunological properties but are differentially regulated by Ca2+ and calmodulin. Accumulating evidence suggests that the A variety of cellular activities are regulated through mech- activity of PDE1 is selectively regulated by cross-talk between anisms controlling the level of cyclic nucleotides. These Ca2+ and cAMP signalling pathways. These isozymes are mechanisms include synthesis, degradation, efflux and seque- also further distinguished by various pharmacological agents. stration of cyclic adenosine 3':5'-monophosphate (cAMP) and We have demonstrated a potentially novel regulation of PDE1 cyclic guanosine 3':5'- monophosphate (cGMP) within the by calpain. -
Novel Variants in Phosphodiesterase 6A and Phosphodiesterase 6B Genes and Its Phenotypes in Patients with Retinitis Pigmentosa in Chinese Families
Novel Variants in Phosphodiesterase 6A and Phosphodiesterase 6B Genes and Its Phenotypes in Patients With Retinitis Pigmentosa in Chinese Families Yuyu Li Beijing Tongren Hospital, Capital Medical University Ruyi Li Beijing Tongren Hospital, Capital Medical University Hehua Dai Beijing Tongren Hospital, Capital Medical University Genlin Li ( [email protected] ) Beijing Tongren Hospital, Capital Medical University Research Article Keywords: Retinitis pigmentosa, PDE6A,PDE6B, novel variants, phenotypes Posted Date: May 20th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-507306/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/15 Abstract Background: Retinitis pigmentosa (RP) is a genetically heterogeneous disease with 65 causative genes identied to date. However, only approximately 60% of RP cases genetically solved to date, predicating that many novel disease-causing variants are yet to be identied. The purpose of this study is to identify novel variants in phosphodiesterase 6A and phosphodiesterase 6B genes and present its phenotypes in patients with retinitis pigmentosa in Chinese families. Methods: Five retinitis pigmentosa patients with PDE6A variants and three with PDE6B variants were identied through a hereditary eye disease enrichment panel (HEDEP), all patients’ medical and ophthalmic histories were collected, and ophthalmological examinations were performed, then we analysed the possible causative variants. Sanger sequencing was used to verify the variants. Results: We identied 20 mutations sites in eight patients, two heterozygous variants were identied per patient of either PDE6A or PDE6B variants, others are from CA4, OPTN, RHO, ADGRA3 variants. We identied two novel variants in PDE6A: c.1246G > A;p.(Asp416Asn) and c.1747T > A;p.(Tyr583Asn). -
Gene Therapy Provides Long-Term Visual Function in a Pre-Clinical Model of Retinitis Pigmentosa Katherine J. Wert Submitted in P
Gene Therapy Provides Long-term Visual Function in a Pre-clinical Model of Retinitis Pigmentosa Katherine J. Wert Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2013 © 2013 Katherine J. Wert All rights reserved ABSTRACT Gene Therapy Provides Long-term Visual Function in a Pre-clinical Model of Retinitis Pigmentosa Katherine J. Wert Retinitis pigmentosa (RP) is a photoreceptor neurodegenerative disease. Patients with RP present with the loss of their peripheral visual field, and the disease will progress until there is a full loss of vision. Approximately 36,000 cases of simplex and familial RP worldwide are caused by a mutation in the rod-specific cyclic guanosine monophosphate phosphodiesterase (PDE6) complex. However, despite the need for treatment, mouse models with mutations in the alpha subunit of PDE6 have not been characterized beyond 1 month of age or used to test the pre- clinical efficacy of potential therapies for human patients with RP caused by mutations in PDE6A. We first proposed to establish the temporal progression of retinal degeneration in a mouse model with a mutation in the alpha subunit of PDE6: the Pde6anmf363 mouse. Next, we developed a surgical technique to enable us to deliver therapeutic treatments into the mouse retina. We then hypothesized that increasing PDE6α levels in the Pde6anmf363 mouse model, using an AAV2/8 gene therapy vector, could improve photoreceptor survival and retinal function when delivered before the onset of degeneration. Human RP patients typically will not visit an eye care professional until they have a loss of vision, therefore we further hypothesized that this gene therapy vector could improve photoreceptor survival and retinal function when delivered after the onset of degeneration, in a clinically relevant scenario. -
Arp73034 P050
Aviva Systems Biology PDE6D Antibody - N-terminal region (ARP73034_P050) Product Number ARP73034_P050 Product Page http://www.avivasysbio.com/pde6d-antibody-n-terminal-region-arp73034-p050.html Product Name PDE6D Antibody - N-terminal region (ARP73034_P050) Size 100 ul Gene Symbol PDE6D Alias Symbols PDE6D, PDED, Protein Size (# AA) 150 amino acids Molecular Weight 16kDa Product Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. NCBI Gene Id 5147 Host Rabbit Clonality Polyclonal Concentration Batch dependent within range: 100 ul at 0.5 - 1 mg/ml Description This is a rabbit polyclonal antibody against PDE6D. It was validated on Western Blot by Aviva Systems Biology. At Aviva Systems Biology we manufacture rabbit polyclonal antibodies on a large scale (200-1000 products/month) of high throughput manner. Our antibodies are peptide based and protein family oriented. We usually provide antibodies covering each member of a whole protein family of your interest. We also use our best efforts to provide you antibodies recognize various epitopes of a target protein. For availability of antibody needed for your experiment, please inquire ([email protected]). Peptide Sequence Synthetic peptide located within the following region: NLRDAETGKILWQGTEDLSVPGVEHEARVPKKILKCKAVSRELNFSSTEQ Description of PDE6D acts as a GTP specific dissociation inhibitor (GDI). It increases the affinity of Target ARL3 for GTP by several orders of magnitude and does so by decreasing the nucleotide dissociation rate. It stabilizes ARL3-GTP by decreasing the nucleotide dissociation. Protein Interactions ARL16; ARL2; UBC; PTGIR; COPS5; CUL1; FAM219A; ARL15; RND1; GRK7; RAD23A; ARL3; CETN3; RAB13; RAB18; RHEB; RPGR; HRAS; GRK1; RAP2B; RAP1A; RHOA; RHOB; RAB8A; GNAI1; RASA1; CDC42; Reconstitution and For short term use, store at 2-8C up to 1 week. -
It Takes Two Transducins to Activate the Cgmp-Phosphodiesterase 6 in Retinal Rods Rsob.Royalsocietypublishing.Org Bilal M
It takes two transducins to activate the cGMP-phosphodiesterase 6 in retinal rods rsob.royalsocietypublishing.org Bilal M. Qureshi1,†,‡, Elmar Behrmann1,†,}, Johannes Scho¨neberg2,jj, Justus Loerke1,Jo¨rg Bu¨rger1, Thorsten Mielke1,3, Jan Giesebrecht1,§, Frank Noe´2, Trevor D. Lamb4, Klaus Peter Hofmann1,5, Christian M. T. Spahn1 and Martin Heck1 Research 1Institut fu¨r Medizinische Physik und Biophysik, Charite´ – Universita¨tsmedizin Berlin, corporate member Cite this article: Qureshi BM et al. 2018 It of Freie Universita¨t Berlin, Humboldt-Universita¨t zu Berlin, and Berlin Institute of Health, Berlin, Germany 2Department of Mathematics, Computer Science and Bioinformatics, Freie Universita¨t Berlin, Berlin, Germany takes two transducins to activate the cGMP- 3Microscopy and Cryo Electron Microscopy Group, Max-Planck Institut fu¨r Molekulare Genetik, Berlin, Germany phosphodiesterase 6 in retinal rods. Open Biol. 4Eccles Institute of Neuroscience, John Curtin School of Medical Research, Australian National University, 8: 180075. Canberra, Australian Capital Territory 2600, Australia 5 http://dx.doi.org/10.1098/rsob.180075 Zentrum fu¨r Biophysik und Bioinformatik, Humboldt-Universita¨t zu Berlin, Berlin, Germany BMQ, 0000-0002-0153-7729; TDL, 0000-0003-0299-6115; MH, 0000-0003-0847-5038 Received: 28 April 2018 Accepted: 6 July 2018 Among cyclic nucleotide phosphodiesterases (PDEs), PDE6 is unique in serving as an effector enzyme in G protein-coupled signal transduction. In Subject Area: retinal rods and cones, PDE6 is membrane-bound and activated to hydrolyse biochemistry/biophysics/structural biology its substrate, cGMP, by binding of two active G protein a-subunits (Ga*). To investigate the activation mechanism of mammalian rod PDE6, we Keywords: have collected functional and structural data, and analysed them by reac- PDE6, visual signal transduction, coincidence tion–diffusion simulations. -
Genetic Variation in Phosphodiesterase (PDE) 7B in Chronic Lymphocytic Leukemia: Overview of Genetic Variants of Cyclic Nucleotide Pdes in Human Disease
Journal of Human Genetics (2011) 56, 676–681 & 2011 The Japan Society of Human Genetics All rights reserved 1434-5161/11 $32.00 www.nature.com/jhg ORIGINAL ARTICLE Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease Ana M Peiro´ 1,2, Chih-Min Tang1, Fiona Murray1,3, Lingzhi Zhang1, Loren M Brown1, Daisy Chou1, Laura Rassenti4, Thomas A Kipps3,4 and Paul A Insel1,3,4 Expression of cyclic adenosine monophosphate-specific phosphodiesterase 7B (PDE7B) mRNA is increased in patients with chronic lymphocytic leukemia (CLL), thus suggesting that variation may occur in the PDE7B gene in CLL. As genetic variation in other PDE family members has been shown to associate with numerous clinical disorders (reviewed in this manuscript), we sought to identify single-nucleotide polymorphisms (SNPs) in the PDE7B gene promoter and coding region of 93 control subjects and 154 CLL patients. We found that the PDE7B gene has a 5¢ non-coding region SNP À347C4T that occurs with similar frequency in CLL patients (1.9%) and controls (2.7%). Tested in vitro, À347C4T has less promoter activity than a wild-type construct. The low frequency of this 5¢ untranslated region variant indicates that it does not explain the higher PDE7B expression in patients with CLL but it has the potential to influence other settings that involve a role for PDE7B. Journal of Human Genetics (2011) 56, 676–681; doi:10.1038/jhg.2011.80; published online 28 July 2011 Keywords: cAMP; chronic lymphocytic